Resources | NITAG RESOURCE CENTER

2024 ∙ NIAC

NIAC Herpes Zoster vaccine recommendations

2024 ∙ NACI

Economic Evidence Supplementary Appendix to the Recommendations for Public Health Programs on the Use of Pneumococcal Vaccines in Children, Including the Use of 15-Valent and 20-Valent Conjugate Vaccines

2024 ∙ NACI

Recommendations for public health programs on the use of pneumococcal vaccines in children, including the use of 15-valent and 20-valent conjugate vaccines

2024 ∙ JCVI

JCVI statement on COVID-19 vaccination in spring 2024 and considerations on future COVID-19 vaccination

2024 ∙ NIAC

Updated recommendations for the vaccination of adults against measles

2024 ∙ ATAGI

ATAGI statement on Nirsevimab for the prevention of severe disease due to respiratory syncytial virus (RSV) in infants

2024 ∙ Louise Henaff, Dace Zavadska, Mario Melgar, Johanna Fihman, Christoph Steffen, Joachim Hombach

The role of NITAGs in government decisions on vaccine use: insights from the Fifth Global NITAG Network meeting

2024 ∙ NACI

Guidance on an additional dose of COVID-19 vaccines in the spring for individuals at high risk of severe illness due to COVID-19

2023 ∙ Eiden, Amanda L. Barratt, Jane Nyaku, Mawuli K.

A review of factors influencing vaccination policies and programs for older adults globally

2023 ∙ Vraga, Emily K. Brady, Sonya S. Gansen, Chloe Khan, Euna Mehnaz Bennis, Sarah L. Nones, Madalyn Tang, Rongwei Srivastava, Jaideep Kulasingam, Shalini

A review of HPV and HBV vaccine hesitancy, intention, and uptake in the era of social media and COVID-19